INmune Bio Inc (INMB)
9.92
-0.10
(-1.00%)
USD |
NASDAQ |
May 13, 16:00
9.88
-0.04
(-0.40%)
After-Hours: 20:00
INmune Bio Net Income (TTM): -34.50M for March 31, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -34.50M |
| December 31, 2023 | -30.01M |
| September 30, 2023 | -27.43M |
| June 30, 2023 | -26.60M |
| March 31, 2023 | -26.93M |
| December 31, 2022 | -27.30M |
| September 30, 2022 | -31.14M |
| June 30, 2022 | -32.87M |
| March 31, 2022 | -32.69M |
| December 31, 2021 | -30.34M |
| September 30, 2021 | -23.87M |
| June 30, 2021 | -19.13M |
| Date | Value |
|---|---|
| March 31, 2021 | -14.58M |
| December 31, 2020 | -12.10M |
| September 30, 2020 | -11.21M |
| June 30, 2020 | -9.563M |
| March 31, 2020 | -7.847M |
| December 31, 2019 | -7.678M |
| September 30, 2019 | -7.24M |
| June 30, 2019 | -5.713M |
| March 31, 2019 | -11.49M |
| December 31, 2018 | -12.44M |
| September 30, 2018 | -10.99M |
| June 30, 2018 | -9.756M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-34.50M
Minimum
Mar 2024
-5.713M
Maximum
Jun 2019
-20.94M
Average
-25.23M
Median
Net Income (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 205.46M |
| Sarepta Therapeutics Inc | 16.90M |
| Dare Bioscience Inc | -30.16M |
| Zevra Therapeutics Inc | -46.05M |
| Kodiak Sciences Inc | -260.49M |